Summary:
- This article discusses the withdrawal of a biologics license application (BLA) for patritumab deruxtecan, a new drug for treating a specific type of lung cancer.
- Patritumab deruxtecan is a targeted therapy that is designed to treat non-small cell lung cancer (NSCLC) with certain genetic mutations in the EGFR gene.
- The withdrawal of the BLA was a voluntary decision by the pharmaceutical company, Daiichi Sankyo, as they work to gather additional data and information to support the application in the future.